Reactivation of hepatitis B two years after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: A note of caution

Clinical Transplantation

Volumn 23, Issue 3, 2009, Pages 431-434

  Gossmann, Jan ^a,b   Scheuermann, Ernst Heinrich ^b   Kachel, Heinz Georg ^a   Geiger, Helmut ^b   Hauser, Ingeborg A ^b  

^a Transplantationsambulanz   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Hepatitis B; Kidney transplantation; Reactivation; Renal transplantation; Rituximab

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BASILIXIMAB; CD19 ANTIBODY; CREATININE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIBODY; HYPERIMMUNE GLOBULIN; LAMIVUDINE; PREDNISONE; RITUXIMAB; TACROLIMUS; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; FOCAL GLOMERULOSCLEROSIS; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; INFECTIOUS HEPATITIS; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; RENAL GRAFT DYSFUNCTION; SIDE EFFECT; VIRUS REACTIVATION;

ADULT; ANTIBODIES, MONOCLONAL; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEPATITIS B; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY TRANSPLANTATION; MALE; RECURRENCE; REOPERATION;

EID: 66849134931     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00936.x     Document Type: Article

References (28)

1. Illidge TM, Bayne MC. Antibody therapy of lymphoma. Expert Opin Pharmacother 2001: 2: 953.
2. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006: 54: 2970.
3. Remuzzi G, Chiurchiu C, A bbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 2002: 360: 923.
4. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004: 4: 996.
5. Benz K, Dotsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 2004: 19: 794.
6. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab tratment. N Engl J Med 2006: 354: 1962.
7. Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 2005: 20: 1660.
8. Gossmann J, Scheuermann EH, Porubsky S, Kachel HG, Geiger H, Hauser IA. Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis. Transpl Int 2007: 20: 558.
9. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients'recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996: 2: 1104.
10. Barclay S, Pol S, Mutimer D et al. Erratum to 'The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting'[J Clin Virol 41 (4) 2008 243-254]. J Clin Virol 2008: 42: 104.
11. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975: 68: 105.
12. Hoofnagle JH, Dusheiko GM, Schafer DF et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982: 96: 447.
13. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006: 43: 209.
14. Dhedin N, Douvin C, Kuentz M et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: A retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998: 66: 616.
15. Yeo W, Chan PKS, Hui P et al. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy: A prospective study. J Med Virol 2003: 70: 553.
16. Jang JW, Choi JY, Bae SH et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 2004: 41: 427.
17. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: Potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005: 46: 1085.
18. Perceau G, Diris N, Estines O, Derancourt C, Levy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006: 155: 1053.
19. Sera T, Hiasa Y, Michitaka K et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006: 45: 721.
20. Nagington J. Reactivation of hepatitis b after transplantation operations. Lancet 1977: 1: 558.
21. Blanpain C, Knoop C, Delforge ML et al. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: Report on three cases and review of the literature. Transplantation 1998: 66: 883.
22. Knöll A, Pietrzyk M, Loss M, Goetz WA, Jilg W. Solid organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: Low risk of HBV reactivation. Transplantation 2005: 79: 1631.
23. Izopet J, Rostaing L, Moussion F et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 1997: 176: 1614.
24. Egwim C, Botero RC. Is hepatitis B immunoglobulin prophylaxis needed for liver transplantation in the era of new antivirals? Transplant Proc 2005: 37: 2200.
25. Dai MS, Wu PF, Lu JJ, Shyu RY, Chao TY. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: A longitudinal study. Support Care Cancer 2004: 12: 191.
26. Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 1999: 94: 249.
27. Lau GK, Yiu HH, Fong DY et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003: 125: 1742.
28. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004: 83: 769.